

Mark-up of the claims showing changes.

17. (AMENDED) A pharmaceutical composition, which comprises a melanin-concentrating hormone antagonist in combination with at least one species selected from the group consisting of an agent for treating diabetes, an agent for treating hypertension and an agent for treating arteriosclerosis and a pharmaceutically acceptable carrier, diluent or excipient.

REMARKS

The specification is amended above to insert a reference to related cases.

The claims have been amended to better conform the claims to accepted U.S. practice.

Support for amendment to claim 17 can be found in the specification as filed.

Claim 39 encompasses the subject matter of cancelled claims 37 and 38, and is supported by the specification as filed.

Claims 40-45 encompass the subject matter of cancelled claim 32, rewritten in dependent form.

No amendment of inventorship is necessitated by these amendments.

A clean copy of the claims as amended are attached for the Examiner's use.


Early allowance of the claims is requested. Should the Examiner believe that a conference with applicants' attorney would advance prosecution of this application, the Examiner is respectfully invited to call applicants' attorney.

Respectfully submitted,

Dated: March 18, 2002

(847)383-3372

(847)383-3391



Mark Chao, Ph.D., Reg. No. 37,293

Elaine M. Ramesh, Ph.D., Reg. No. 43032

Attorney for Applicants

Customer No. 23115

Takeda Pharmaceuticals North America, Inc.
Intellectual Property Department
Suite 500, 475 Half Day Road
Lincolnshire, IL 60069 USA